Free tool
FAERS Monitor: Cyltezo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761058 or its brand name (Cyltezo, Adalimumab-Adbm). Reports on generic versions are filed under their own applications.
Reports
268
Serious
58
22% of reports
Hospitalization
26
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device malfunction26
- drug ineffective18
- injection site haemorrhage18
- pain18
- injection site pain17
- off label use16
- device issue14
- diarrhoea12
- arthralgia11
- wrong technique in product usage process11
- needle issue10
- fatigue9
- haemorrhage9
- injection site bruising9
- device mechanical issue8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2023 | 4 |
| 2024 | 25 |
| 2025 | 95 |
| 2026 | 143 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,891 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device mechanical issueSignal | 8 | 45.8 | 23.1 | 307 |
| device malfunctionSignal | 26 | 29.0 | 20.2 | 678 |
| needle issueSignal | 10 | 27.0 | 14.7 | 225 |
| injection site haemorrhageSignal | 18 | 17.7 | 11.3 | 268 |
| device issueSignal | 14 | 12.3 | 7.4 | 134 |
| injection site bruisingSignal | 9 | 8.9 | 4.7 | 55 |
| haemorrhageSignal | 9 | 6.8 | 3.6 | 39 |
| injection site painSignal | 17 | 4.3 | 2.7 | 41 |
| wrong technique in product usage processSignal | 11 | 4.3 | 2.4 | 25 |
| painSignal | 18 | 2.3 | 1.5 | 12 |
| arthralgiaSignal | 11 | 2.1 | 1.2 | 5 |
| diarrhoea | 12 | 1.5 | 0.8 | 1 |
| off label use | 16 | 1.4 | 0.9 | 2 |
| drug ineffective | 18 | 1.1 | 0.7 | 0 |
| fatigue | 9 | 0.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.